Shots:

• Galimedix will receive an up front technology access fee, success-based milestones along with royalties. Equity investment into Galimedix supports Galimedix's pipeline development
• TOI gets an exclusive right to develop & commercialize Galimedix’s GAL-101 for topical & oral treatment of dry AMD, glaucoma & other ophthalmic indications in the EU, the Americas, the Middle East & Africa. Clinical P-II/III trials with GAL-101 can now begin & 1st patient is expected to be enrolled in 2024 with initial clinical efficacy results expected about 18mos. later
• TOI will be responsible for fully funding the remaining development of GAL-101 & lead the registration and commercialization of the drug. Galimedix will lead the mid-stage clinical trials & continue to extend its pipeline incl. AD
   

  Ref: théa | Image: théa